"Cost-Benefit Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.
| Descriptor ID |
D003362
|
| MeSH Number(s) |
N03.219.151.125
|
| Concept/Terms |
Cost-Benefit Analysis- Cost-Benefit Analysis
- Analyses, Cost-Benefit
- Analysis, Cost-Benefit
- Cost-Benefit Analyses
- Cost Benefit Analysis
- Analyses, Cost Benefit
- Analysis, Cost Benefit
- Cost Benefit Analyses
Cost-Utility Analysis- Cost-Utility Analysis
- Analyses, Cost-Utility
- Analysis, Cost-Utility
- Cost Utility Analysis
- Cost-Utility Analyses
Economic Evaluation- Economic Evaluation
- Economic Evaluations
- Evaluation, Economic
- Evaluations, Economic
Marginal Analysis- Marginal Analysis
- Analyses, Marginal
- Analysis, Marginal
- Marginal Analyses
Cost Benefit- Cost Benefit
- Costs and Benefits
- Benefits and Costs
|
Below are MeSH descriptors whose meaning is more general than "Cost-Benefit Analysis".
Below are MeSH descriptors whose meaning is more specific than "Cost-Benefit Analysis".
This graph shows the total number of publications written about "Cost-Benefit Analysis" by people in this website by year, and whether "Cost-Benefit Analysis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 2 | 3 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 7 | 7 |
| 2012 | 0 | 4 | 4 |
| 2013 | 0 | 10 | 10 |
| 2014 | 3 | 6 | 9 |
| 2015 | 3 | 4 | 7 |
| 2016 | 2 | 7 | 9 |
| 2017 | 6 | 11 | 17 |
| 2018 | 2 | 10 | 12 |
| 2019 | 3 | 9 | 12 |
| 2020 | 2 | 11 | 13 |
| 2021 | 2 | 11 | 13 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 8 | 8 |
| 2024 | 6 | 6 | 12 |
| 2025 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cost-Benefit Analysis" by people in Profiles.
-
24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation. Lancet Glob Health. 2025 Feb; 13(2):e355-e363.
-
Evaluating the socioeconomic benefits of heat-health warning systems. Eur J Public Health. 2025 Feb 01; 35(1):178-186.
-
Integrated multi-month dispensing for HIV and hypertension in South Africa: A model of epidemiological impact and cost-effectiveness. J Int AIDS Soc. 2025 Feb; 28(2):e26413.
-
Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa. BMC Health Serv Res. 2025 Jan 18; 25(1):100.
-
Ten-year health impact, economic impact and return on investment of the South African molecular diagnostics programme for HIV, tuberculosis and SARS-CoV-2. BMJ Glob Health. 2024 Dec 03; 9(12).
-
Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis. PLoS One. 2024; 19(10):e0309034.
-
Cost-effectiveness of SARS-CoV-2 self-testing at routine gatherings to minimize community-level infections in lower-middle income countries: A mathematical modeling study. PLoS One. 2024; 19(10):e0311198.
-
Letter to the Editor: "Cost-effectiveness and budget impact analysis of the implementation of differentiated service delivery models for HIV treatment in Mozambique: a modelling study": Resource reductions are not equal to cost savings. J Int AIDS Soc. 2024 Oct; 27(10):e26367.
-
Cost-effectiveness of COVID rapid diagnostic tests for patients with severe/critical illness in low- and middle-income countries: A modeling study. PLoS Med. 2024 Jul; 21(7):e1004429.
-
A cost-effectiveness analysis of early detection and bundled treatment of postpartum hemorrhage alongside the E-MOTIVE trial. Nat Med. 2024 Aug; 30(8):2343-2348.